Y27632   Click here for help

GtoPdb Ligand ID: 5290

Synonyms: ROCK Inhibitor, Y-27632 | Y-27632
PDB Ligand
Compound class: Synthetic organic
Comment: We represent the compound as drawn in the article by Wu et al (2010) [5]. Note that the PubChem entry for this compound is missing stereochemistry.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 68.01
Molecular weight 247.17
XLogP 0.86
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C1CCC(CC1)C(=O)Nc1ccncc1)N
Isomeric SMILES C[C@H]([C@@H]1CC[C@H](CC1)C(=O)Nc1ccncc1)N
InChI InChI=1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11-,12-/m1/s1
InChI Key IYOZTVGMEWJPKR-IJLUTSLNSA-N
References
1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Nat Biotechnol, 29 (11): 1039-45. [PMID:22037377]
2. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013)
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Biochem J, 451 (2): 313-28. [PMID:23398362]
3. Löhn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, Schaefer M, Linz W, Kohlmann M, Herbert JM et al.. (2009)
Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor.
Hypertension, 54 (3): 676-83. [PMID:19597037]
4. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M et al.. (1997)
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension.
Nature, 389 (6654): 990-4. [PMID:9353125]
5. Wu F, Büttner FH, Chen R, Hickey E, Jakes S, Kaplita P, Kashem MA, Kerr S, Kugler S, Paw Z et al.. (2010)
Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Bioorg Med Chem Lett, 20 (11): 3235-9. [PMID:20462760]